Speaker
![Antoni Ribas](_common/updateable/img/speakers/bio-Ribas.jpg)
Antoni Ribas , MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA. His research is focused on laboratory and clinical studies to address primary and acquired resistance to immunotherapy and targeted therapies for melanoma, and in the development of gene-engineered adoptive T cell transfer therapies for cancer. He has been instrumental in the clinical development of several agents approved by the FDA, including the first anti-PD-1 pembrolizumab (Keytruda), two combinations of BRAF and MEK inhibitors vemurafenib (Zelboraf) and cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist), and was involved in the development of the first CD19 CAR for lymphoma axicabtagene ciloleucel (Yescarta). He is the recipient of an AACR Richard and Hinda Rosenthal Award, a William B. Coley Award from Cancer Research Institute (CRI), a AACR-CRI Lloyd J. Old Award in Cancer Immunology, two NCI Outstanding Investigator Awards and other awards. He is a past president of the American Association for Cancer Research (AACR), an elected Fellow of the AACR Academy, the Royal Academy of Medicine of Catalonia, the American Society of Clinical Investigation, and the National Academy of Medicine.
« Go Back